Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal...
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal...
Background— The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks’ sodium glucose cotransporter 2 inhibition wit...
ClinicalTrials.gov Identifier: NCT01897532.
h-index: Number of publications with at least h citations each.